Cognition Therapeutics Will Meet FDA October 20

The company will discuss plans for a Phase 3 trial of zervimesine to treat psychosis in DLB patients.

Updated on Sept. 29, 2026 in Alzheimer’s

Bold flat-color editorial illustration of a glass vial and molecular structure, representing the clinical trial process. — Cognition Therapeutics is set to meet with FDA regulators on October 20 to determine clinical trial pathways for its dementia drug zervimesine. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies prioritize developing treatments for psychosis symptoms in neurodegenerative disease patients?

Cognition Therapeutics has scheduled a Type C meeting with the FDA for October 20, 2026, to align on clinical trial requirements. The discussion will focus on statistical details for a planned Phase 3 study of the drug zervimesine for dementia with Lewy bodies.

Why it matters

Currently, there are no FDA-approved medications specifically for treating symptoms of dementia with Lewy bodies (DLB). Securing an agreement on clinical endpoints is a critical step for Cognition Therapeutics to advance its treatment into a registrational study.

In a Phase 2 trial, zervimesine showed an 89% reduction in the progression of hallucinations and delusions. Approximately 80% of DLB patients experience psychosis, yet no drugs are currently approved to treat these specific symptoms.

The players

Cognition Therapeutics

This is a Purchase, New York-based clinical-stage biopharmaceutical company that develops drugs for neurodegenerative diseases.

FDA Division of Neurology

This regulatory body is responsible for evaluating the safety and efficacy of new drug applications related to neurological conditions.

The details

The planned Phase 3 study design involves randomizing participants to receive either a 100 mg daily oral dose of zervimesine or a placebo for nine months. Participants will be eligible to enroll regardless of their background medication usage as the company seeks to validate psychosis as an approvable outcome.

June 2026: Cognition Therapeutics received meeting minutes from the FDA.
September 29, 2026: The company announced the upcoming FDA meeting.
October 20, 2026: The Type C meeting with the FDA is scheduled to take place.

Cancer
Sept. 28
NeOnc Will Meet With FDA on November 17, 2026
Alzheimer’s
Sept. 25
FDA Maintained Clinical Hold on Newron Study
Alzheimer’s
Sept. 18
Xenon Pharmaceuticals Submitted Drug Application to FDA

The Big Picture

The meeting follows the precedent established by the FDA's previous agreement that psychosis can be an approvable clinical outcome for DLB studies. This alignment helps bridge the gap for companies seeking regulatory pathways for orphan neurodegenerative indications.

This development could eventually provide a new, dedicated treatment option for the 80% of DLB patients who currently struggle with psychosis symptoms without approved medication. No immediate changes to existing treatment routines are expected until the Phase 3 trial completes.

The takeaway

This meeting is a pivotal step in potentially bringing the first targeted treatment for DLB psychosis to market. Families of patients should continue to consult with their neurologists regarding standard care while awaiting the results of future clinical trials.